Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-01-12 @ 2:05 PM
Study NCT ID:
NCT02019420
Status:
COMPLETED
Last Update Posted:
2019-06-27
First Post:
2013-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-01-06
Start Date Type:
ACTUAL
Primary Completion Date:
2018-06-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06-22
Completion Date Type:
ACTUAL
First Submit Date:
2013-12-18
First Submit QC Date:
None
Study First Post Date:
2013-12-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-10
Results First Submit QC Date:
None
Results First Post Date:
2019-06-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-10
Last Update Post Date:
2019-06-27
Last Update Post Date Type:
ACTUAL